

NHSBT Hepatitis E Virus (HEV) Factsheet for Hospital Transfusion Teams – January 2016

	Subject	Information	Action for Hospitals
1	Time frame for introduction of components screened for HEV RNA (referred to as 'HEV negative' in this document)	<ul style="list-style-type: none"> • NHSBT aims to have full stock availability of HEV negative components by 14th March. From this date you will be able to start ordering components. • Stock building: <ul style="list-style-type: none"> ○ RBCs: please gradually build stocks over 2 weeks. ○ Platelets: please stock as required. ○ Frozen components: please gradually build stocks over 3 weeks. • Recent survey results have indicated that there is a large variance in predicted demand for HEV components across Trusts and we are aware that this demand could change following recent clarification of the SaBTO recommendations. We will be closely observing demand for these components over the next few months and we will adjust operations accordingly. 	<ul style="list-style-type: none"> • Continue work on your laboratory information systems (LIMS) to identify patients who require HEV negative components. • Identify stock levels for these components. • Ensure clinical teams for the specific patient groups are aware of the SaBTO guidelines. • Work with clinical teams to develop systems to identify and administer HEV screened components to the specific patient groups
2	Online Blood Ordering System (OBOS)	<ul style="list-style-type: none"> • OBOS will include a 'tick box' for HEV negative components from overnight on 31st January 2016. Please note that there is a gap of six weeks between OBOS changes and full stock availability. • DO NOT use this tick box from 31st January to the 13th March. • If the box is ticked during this period then you will be asked to reorder the component. • From the 14th March the tick box will need to be manually selected except for components that have HEV neg as part of the mandatory requirements. As stated in the table below, there is no requirement to select this tick box for these components. • Methylene Blue (MB) treated frozen components are already screened for HEV during manufacture in Austria. When ordering these components via OBOS, DO NOT tick the HEV box. If this occurs our system will not allow for the component to be dispatched and the component will need to be re-ordered. 	<ul style="list-style-type: none"> • Ensure all staff are updated about the changes.

Subject		Information		Action for Hospitals																																		
		<table border="1"> <thead> <tr> <th style="background-color: #D3D3D3;">Component Required (including irradiated)</th> <th style="background-color: #D3D3D3;">Do you need to tick the HEV box on OBOS?</th> </tr> </thead> <tbody> <tr><td>Red Cells</td><td>Yes</td></tr> <tr><td>Platelets (ATD)</td><td>Yes</td></tr> <tr><td>Washed Red Cells Ext. Life</td><td>Yes</td></tr> <tr><td>Fresh Frozen Plasma</td><td>Yes</td></tr> <tr><td>Cryoprecipitate (Adult Single and Pooled)</td><td>Yes</td></tr> <tr><td>Neonatal Red Cells</td><td>No</td></tr> <tr><td>Exchange Red Cells Irradiated (Neonatal)</td><td>No</td></tr> <tr><td>Large Vol. RBC in SAGM</td><td>No</td></tr> <tr><td>IUT Red Cells</td><td>No</td></tr> <tr><td>Neonatal Platelets</td><td>No</td></tr> <tr><td>IUT Platelets</td><td>No</td></tr> <tr><td>Paediatric MB FFP Non UK</td><td>No</td></tr> <tr><td>Neonatal MB FFP Non UK</td><td>No</td></tr> <tr><td>Cryoprecipitate Single MB Non UK</td><td>No</td></tr> <tr><td>Cryo Pooled MB Non UK</td><td>No</td></tr> <tr><td>Granulocytes Pooled (Irradiated)</td><td>No</td></tr> </tbody> </table>	Component Required (including irradiated)	Do you need to tick the HEV box on OBOS?	Red Cells	Yes	Platelets (ATD)	Yes	Washed Red Cells Ext. Life	Yes	Fresh Frozen Plasma	Yes	Cryoprecipitate (Adult Single and Pooled)	Yes	Neonatal Red Cells	No	Exchange Red Cells Irradiated (Neonatal)	No	Large Vol. RBC in SAGM	No	IUT Red Cells	No	Neonatal Platelets	No	IUT Platelets	No	Paediatric MB FFP Non UK	No	Neonatal MB FFP Non UK	No	Cryoprecipitate Single MB Non UK	No	Cryo Pooled MB Non UK	No	Granulocytes Pooled (Irradiated)	No		
Component Required (including irradiated)	Do you need to tick the HEV box on OBOS?																																					
Red Cells	Yes																																					
Platelets (ATD)	Yes																																					
Washed Red Cells Ext. Life	Yes																																					
Fresh Frozen Plasma	Yes																																					
Cryoprecipitate (Adult Single and Pooled)	Yes																																					
Neonatal Red Cells	No																																					
Exchange Red Cells Irradiated (Neonatal)	No																																					
Large Vol. RBC in SAGM	No																																					
IUT Red Cells	No																																					
Neonatal Platelets	No																																					
IUT Platelets	No																																					
Paediatric MB FFP Non UK	No																																					
Neonatal MB FFP Non UK	No																																					
Cryoprecipitate Single MB Non UK	No																																					
Cryo Pooled MB Non UK	No																																					
Granulocytes Pooled (Irradiated)	No																																					
3	Electronic Despatch Note (EDN)	<ul style="list-style-type: none"> EDN changes will be made to support the introduction of HEV negative components. All hospitals received a communication from NHSBT on 8th January 2016 noting the addition of HEV to the EDN specification in the Guidelines for UK Blood Transfusion Services Chapter 25. 		<ul style="list-style-type: none"> If you use EDN, contact your laboratory information system supplier to ensure all changes required are implemented. 																																		
4	Component label and product code	<ul style="list-style-type: none"> NHSBT will not be testing all components for HEV. If the component has been tested by NHSBT and is HEV negative this will be indicated on the component label as 'NEG: HEV'. All Methylene Blue (MB) treated frozen components are HEV negative but will not be labelled HEV negative (see point 2). There will not be a specific barcode on the label relating to HEV negative components. The HEV negative components will not have new product codes. 		<p style="text-align: center;">Rh D POSITIVE Expiry Date: 20 Jan 2016 Additional Information NEG: K,Fya,HEV Date Bled: 05 Jan 2016</p>																																		

	Subject	Information	Action for Hospitals
5	Specific Components	<ul style="list-style-type: none"> • Methylene Blue (MB) Treated Frozen Components: <ul style="list-style-type: none"> ○ The imported plasma used to manufacture MB treated frozen components is HEV screened at source (see point 2 re OBOS requirements). • Granulocytes: <ul style="list-style-type: none"> ○ NHSBT is adjusting its manufacturing process to ensure granulocyte components are HEV screened and confirmed as negative prior to distribution. ○ Granulocytes consist of 10 donations and we need to test each donation prior to pooling the component. ○ We will issue these components as soon as they are ready but HEV testing may have an effect on time of issue. We will be monitoring issue times carefully and at the moment we will not be changing the SLA. 	<ul style="list-style-type: none"> • Ensure clinicians are aware of the potential change to the administration time.
6	Cost of components	<ul style="list-style-type: none"> • As previously communicated, there will be an 'addval' charge for these components of £17.18 per component. • The additional charge will come into effect on 1st April 2016. • There is no addval charge for components where HEV negative is part of the specification or for MB treated components that are tested at source. • If you receive HEV negative components and you have not requested them, you will not be charged. • The 'addval' charge will be reviewed after the first few months and if it proves to have been too high then a rebate will be paid to hospitals (in proportion to their order levels) and the charge level reviewed. 	<ul style="list-style-type: none"> • For large users of HEV negative components this may pose a significant cost pressure. If you have not already done so, it is important you contact your finance department and put processes in place to assess and monitor your own demand.
7	Patient Information	<ul style="list-style-type: none"> • NHSBT is producing a HEV Patient Factsheet which will be available to download from the Hospitals and Science website prior to the introduction of HEV negative components. • Further education materials are being developed to support safe administration and appropriate use of these special components. 	